Literature DB >> 6368059

A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis.

J C Homberg, C Andre, N Abuaf.   

Abstract

The sera of 131 patients with anti-liver-kidney microsome antibodies (anti-LKM) detected between 1973 and 1979 in two different laboratories were re-examined. (1) Eighty-six anti-LKM corresponded to the description given by Rizzetto, Swana & Doniach (1973), with a pattern of fluorescence predominating on the 3rd portion of the proximal tubules (P3). This group comprised 45 cases of idiopathic chronic hepatitis or idiopathic cirrhosis and one case of halothane-induced hepatitis. (2) Forty-five anti-LKM gave a different pattern on male mouse liver and male rat kidney: (a) fluorescence was greater on centrolobular than on periportal hepatocytes; (b) the first and second portions of proximal tubules (P1 and P2) predominated over P3; (c) P1 fluorescence was equally intense as P2 and (d) P3 cells were heterogeneous with one cell out of 20 more positive than the rest. Absorption tests confirmed that the corresponding antigen was also present in the liver microsomal fraction. A retrospective clinical study discovered tienilic acid-induced hepatitis in all cases. We suggest naming this new antibody 'anti-LKM2'.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6368059      PMCID: PMC1535915     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Characterization of the microsomal antigen related to a subclass of active chronic hepatitis.

Authors:  M Rizzetto; F B Bianchi; D Doniach
Journal:  Immunology       Date:  1974-03       Impact factor: 7.397

2.  [Lupus erythematosus-like syndrome with antimitochondrial antibodies].

Authors:  D Maas; H Schubothe
Journal:  Dtsch Med Wochenschr       Date:  1973-01-26       Impact factor: 0.628

3.  Microsomal antibodies in active chronic hepatitis and other disorders.

Authors:  M Rizzetto; G Swana; D Doniach
Journal:  Clin Exp Immunol       Date:  1973-11       Impact factor: 4.330

Review 4.  Cooperating and controlling functions of thymus-derived lymphocytes in relation to autoimmunity.

Authors:  A C Allison; A M Denman; R D Barnes
Journal:  Lancet       Date:  1971-07-17       Impact factor: 79.321

5.  Erythrocyte autoantibodies induced in mice immunized with rat erythrocytes.

Authors:  K O Cox; D Keast
Journal:  Immunology       Date:  1973-09       Impact factor: 7.397

6.  [Cytolytic hepatitis, role of tienilic acid].

Authors:  P Groussin; D Chavanne; J P Renard; M Medelsi; B Arbeille-Brassard; D Royere
Journal:  Med Chir Dig       Date:  1979

7.  Drug-induced pseudolupus.

Authors:  P J Grob; J W Müller-Schoop; M A Häcki; H I Joller-Jemelka
Journal:  Lancet       Date:  1975-07-26       Impact factor: 79.321

8.  Unexplained hepatitis following halothane.

Authors:  B Walton; B R Simpson; L Strunin; D Doniach; J Perrin; A J Appleyard
Journal:  Br Med J       Date:  1976-05-15

9.  [Liver diseases with microsomal antibodies. Frequency, clinical and immunological findings and course observations (author's transl)].

Authors:  G Schmidt; J Kienle; D S Schmidt; H Wolf
Journal:  Z Gastroenterol       Date:  1978-08       Impact factor: 2.000

10.  Hepatic disorders associated with liver-kidney microsomal antibodies.

Authors:  M G Smith; R Williams; G Walker; M Rizzetto; D Doniach
Journal:  Br Med J       Date:  1974-04-13
View more
  29 in total

Review 1.  Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update.

Authors:  E Boitier; P Beaune
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 2.  Autoantibodies as prognostic markers in autoimmune liver disease.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-05-13       Impact factor: 3.199

Review 3.  Cytochrome P450 enzymes as human autoantigens.

Authors:  M P Manns
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 4.  Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib.

Authors:  Han Kiat Ho; James Chun Yip Chan; Klarissa D Hardy; Eric Chun Yong Chan
Journal:  Drug Metab Rev       Date:  2015-02-02       Impact factor: 4.518

5.  An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis.

Authors:  Akiko Hisamochi; Masayoshi Kage; Tatsuya Ide; Teruko Arinaga-Hino; Keisuke Amano; Reiichiro Kuwahara; Kei Ogata; Ichiro Miyajima; Ryukichi Kumashiro; Michio Sata; Takuji Torimura
Journal:  J Gastroenterol       Date:  2015-10-30       Impact factor: 7.527

6.  Chronic active hepatitis associated with liver-kidney microsomal antibody of an autoimmune type. Two familial cases.

Authors:  C Buffet; J C Homberg; G Pelletier; K Turner; J P Etienne
Journal:  Dig Dis Sci       Date:  1986-11       Impact factor: 3.199

7.  Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis.

Authors:  M Bourdi; D Larrey; J Nataf; J Bernuau; D Pessayre; M Iwasaki; F P Guengerich; P H Beaune
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

8.  Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways.

Authors:  Xiaohai Li; Yuanjun He; Claudia H Ruiz; Marcel Koenig; Michael D Cameron; Tomas Vojkovsky
Journal:  Drug Metab Dispos       Date:  2009-03-12       Impact factor: 3.922

9.  Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera.

Authors:  M A Robin; M Maratrat; M Le Roy; F P Le Breton; E Bonierbale; P Dansette; F Ballet; D Mansuy; D Pessayre
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

10.  Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.

Authors:  U M Zanger; H P Hauri; J Loeper; J C Homberg; U A Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.